Several brokerages have updated their recommendations and price targets on shares of Insmed (NASDAQ: INSM) in the last few weeks:
- 7/12/2024 – Insmed had its price target raised by analysts at Morgan Stanley from $60.00 to $85.00. They now have an “overweight” rating on the stock.
- 7/10/2024 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $102.00. They now have a “buy” rating on the stock.
- 7/9/2024 – Insmed had its price target raised by analysts at Guggenheim from $70.00 to $95.00. They now have a “buy” rating on the stock.
- 7/8/2024 – Insmed had its price target raised by analysts at HC Wainwright from $70.00 to $90.00. They now have a “buy” rating on the stock.
- 7/5/2024 – Insmed had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $83.00 price target on the stock.
- 7/2/2024 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
- 7/1/2024 – Insmed had its price target raised by analysts at Truist Financial Co. from $68.00 to $88.00. They now have a “buy” rating on the stock.
- 6/28/2024 – Insmed had its price target raised by analysts at Bank of America Co. from $62.00 to $83.00. They now have a “buy” rating on the stock.
- 6/21/2024 – Insmed had its price target raised by analysts at Evercore ISI from $42.00 to $75.00. They now have an “outperform” rating on the stock.
- 6/20/2024 – Insmed had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
- 6/20/2024 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $72.00. They now have an “overweight” rating on the stock.
- 6/7/2024 – Insmed had its price target raised by analysts at Mizuho from $36.00 to $82.00. They now have a “buy” rating on the stock.
- 5/31/2024 – Insmed had its price target raised by analysts at Stifel Nicolaus from $39.00 to $67.00. They now have a “buy” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at Wells Fargo & Company from $55.00 to $77.00. They now have an “overweight” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $36.00 to $55.00. They now have an “overweight” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at Barclays PLC from $40.00 to $63.00. They now have an “overweight” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at TD Cowen from $45.00 to $67.00. They now have a “buy” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $49.00 to $74.00. They now have a “buy” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at UBS Group AG from $46.00 to $58.00. They now have a “buy” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at Truist Financial Co. from $48.00 to $68.00. They now have a “buy” rating on the stock.
- 5/29/2024 – Insmed had its price target raised by analysts at HC Wainwright from $52.00 to $70.00. They now have a “buy” rating on the stock.
- 5/28/2024 – Insmed had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $40.00 price target on the stock.
Insmed Stock Up 0.1 %
Shares of NASDAQ:INSM traded up $0.07 during trading on Thursday, hitting $74.50. The stock had a trading volume of 1,716,709 shares, compared to its average volume of 2,555,528. Insmed Incorporated has a 12-month low of $20.28 and a 12-month high of $78.87. The stock has a market capitalization of $11.07 billion, a price-to-earnings ratio of -14.24 and a beta of 1.16. The stock has a 50-day simple moving average of $59.39 and a two-hundred day simple moving average of $38.51.
Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.16. The company had revenue of $75.50 million for the quarter, compared to analysts’ expectations of $77.76 million. The firm’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.17) earnings per share. As a group, sell-side analysts forecast that Insmed Incorporated will post -4.71 earnings per share for the current year.
Insider Activity at Insmed
Institutional Trading of Insmed
Several institutional investors have recently bought and sold shares of INSM. International Assets Investment Management LLC acquired a new stake in shares of Insmed in the fourth quarter worth approximately $25,000. EntryPoint Capital LLC acquired a new stake in shares of Insmed in the first quarter worth approximately $33,000. Fidelis Capital Partners LLC acquired a new stake in shares of Insmed in the first quarter worth approximately $34,000. First Horizon Advisors Inc. boosted its stake in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Insmed in the first quarter worth approximately $59,000.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Articles
- Five stocks we like better than Insmed
- Financial Services Stocks Investing
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- How to Invest in the Best Canadian Stocks
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Insmed Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.